Phase II Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma

The purpose of this study is to obtain safety and efficacy data using tositumomab or Bexxar in patients with relapsed/refractory diffuse large cell Non-Hodgkin's lymphoma (DLCL).

Principal Investigator

CONTACT INFORMATION

Primary Contact:
Lucy Schoen
(650) 725-1718